Daiichi Sankyo
Japanese pharmaceutical company

Daiichi Sankyo Co., Ltd. is a global pharmaceutical company and one of the largest in Japan. It was established in 2005 through the merger of two companies, Daiichi Pharmaceutical and Sankyo Co., Ltd. The company is headquartered in Tokyo, Japan, and is known for its research and development in the field of cardiovascular disease, oncology, and immunology.
History[edit]
Daiichi Sankyo was formed in 2005, but its roots trace back to the early 20th century. Sankyo Co., Ltd. was founded in 1899, and Daiichi Pharmaceutical was established in 1915. Both companies played significant roles in the development of the Japanese pharmaceutical industry.
Merger[edit]
The merger of Daiichi Pharmaceutical and Sankyo Co., Ltd. was driven by the need to compete on a global scale and to pool resources for more effective research and development. The merger created a company with a strong portfolio of products and a robust pipeline of new drugs.
Research and Development[edit]
Daiichi Sankyo is heavily invested in R&D and has several research facilities around the world. The company's research focuses on three main areas:
- Cardiovascular Disease: Developing treatments for hypertension, hyperlipidemia, and other cardiovascular conditions.
- Oncology: Focusing on innovative therapies for various types of cancer.
- Immunology: Researching treatments for autoimmune diseases and other immune-related conditions.
Products[edit]
Daiichi Sankyo offers a wide range of pharmaceutical products. Some of its well-known products include:
- Olmesartan: An antihypertensive medication used to treat high blood pressure.
- Edoxaban: An anticoagulant used to prevent stroke and venous thromboembolism.
- Prasugrel: An antiplatelet drug used to prevent blood clots in patients with acute coronary syndrome.
Global Presence[edit]
Daiichi Sankyo operates in over 20 countries and has a strong presence in the United States, Europe, and Asia. The company collaborates with various international partners to enhance its global reach and to bring innovative therapies to patients worldwide.
Corporate Social Responsibility[edit]
Daiichi Sankyo is committed to corporate social responsibility (CSR) and sustainability. The company focuses on improving access to healthcare, reducing its environmental impact, and supporting community initiatives.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian